THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Tuesday, April 04, 2023
The new instrument offers unprecedented throughput and efficiency for discovering and characterizing novel therapeutics.
FREMONT, CA: “This is a great day for biologics discovery scientists and for Carterra. You always run the risk of missed expectations when you launch a follow-on product after a game changer like the LSA. But we've proved that with the LSAXT the story only gets better for us and our customers,” says Christopher Silva, Vice President of Marketing and Product at Carterra, speaking about the launch of the LSAXT at SLAS 2023. At the Society for Laboratory Automation and Screening (SLAS) Conference and Exhibition in San Diego, CA, Carterra, the global pioneer in novel technologies allowing high-throughput biology, debuted their newest HT-SPR equipment, the LSAXT. The LSAXT adds enhanced sensitivity to Carterra's very successful LSA platform, enabling expanded applications throughout the drug discovery and development at unprecedented throughput levels. Carterra will demonstrate the new LSAXT platform for high-throughput SPR at the SLAS conference (booth 2127) with a launch program that includes a user presentation by Dragonfly Therapeutics on February 27 at 2:00 pm.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
The LSAXT instrument includes additional hardware and software features that enhance the capabilities of Carterra's original and wildly successful LSA instrument while retaining its excellent throughput and sample efficiency. The LSA provides a hundredfold more data in a tenth of the time-to-answer, with only one percent of the sample required by existing label-free platforms. The LSAXT enables an expanded range of applications, including some of the most exciting and expanding areas of drug discovery, such as proteolysis-targeting chimeras (PROTAC...s), membrane proteins, DNA-Encoded Library (DEL) compounds, and rapid kinetic systems, including cytokines, protein-protein inhibitors, and Fc gamma receptors. In addition, the LSAXT's enhanced performance permits the analysis of analytes with reduced molecular weight, such as kinase inhibitors.
Since its introduction in 2018, Carterra's LSA antibody discovery and characterization platform has been adopted by 19 of the 20 major pharmaceutical companies, CROs, and biotech organizations across four continents. Characterizing many antibodies' binding kinetics and epitope coverage early in the drug discovery process has had a revolutionary effect. Compared to conventional procedures, the rate at which antibodies can now be identified and described as potential treatments has increased dramatically. The LSA platform has been profiled in multiple Science, Nature, and Cell peer-reviewed papers, including one that described the development of a novel monoclonal antibody therapeutic, bamlanivimab, which was the world's first COVID-19 therapeutic and the fastest biologic ever to reach clinical trials, thanks to Eli Lilly and AbCellera.
At SLAS, Dragonfly Therapeutics experts will present the advantages of running the Fc gamma receptor (FcÎ3R) binding application, a crucial component of ADCC, ADCP, and CDC and an essential characteristic to detect in Fc-containing compounds. The capacity to characterize a whole panel of biotinylated FcÎ3Rs is now possible with the Carterra LSAXT's throughput and increased versatility, leading to much faster time to results and sample efficiency than 8-channel biosensor instruments now available on the market.
More in News